ULTRAGENYX PHARMACEUTICAL INC. - COMMON STOCK

Ultragenyx and GeneTx Provide Program Update on GTX-102 for Angelman Syndrome Including Promising Interim Data from Phase 1/2 Study

18 يوليو 2022 15:00:00 بحسب Nasdaq GlobeNewswire

Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $500 Million to OMERS Capital Markets

14 يوليو 2022 07:30:00 بحسب Nasdaq GlobeNewswire

Ultragenyx to Present at Goldman Sachs Global Healthcare Conference

10 يونيو 2022 07:00:00 بحسب Nasdaq GlobeNewswire

Ultragenyx to Present at Jefferies Global Healthcare Conference

01 يونيو 2022 15:01:00 بحسب Nasdaq GlobeNewswire

Ultragenyx Announces Positive Longer-term Durability Data from Two Phase 1/2 Gene Therapy Studies at American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting

19 مايو 2022 07:00:01 بحسب Nasdaq GlobeNewswire

Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome Type A (MPS IIIA) from Abeona Therapeutics

17 مايو 2022 07:00:02 بحسب Nasdaq GlobeNewswire

Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting

09 مايو 2022 07:00:01 بحسب Nasdaq GlobeNewswire

Ultragenyx Reports First Quarter 2022 Financial Results and Corporate Update

05 مايو 2022 15:05:02 بحسب Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

03 مايو 2022 16:00:00 بحسب Nasdaq GlobeNewswire

Ultragenyx to Participate at BofA Securities 2022 Healthcare Conference

03 مايو 2022 15:05:01 بحسب Nasdaq GlobeNewswire

Ultragenyx to Host Conference Call for First Quarter 2022 Financial Results and Corporate Update

27 أبريل 2022 15:01:00 بحسب Nasdaq GlobeNewswire

Ultragenyx Issues Inaugural Environmental, Social and Governance (ESG) Report

25 أبريل 2022 12:18:09 بحسب Nasdaq GlobeNewswire

Ultragenyx Appoints Amrit Ray, M.D., M.B.A. to Board of Directors

22 أبريل 2022 07:00:00 بحسب Nasdaq GlobeNewswire

Ultragenyx Announces First Patient Dosed in Pivotal Phase 2/3 Clinical Study of Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta

20 أبريل 2022 07:00:01 بحسب Nasdaq GlobeNewswire

Ultragenyx to Participate in the Cowen Health Care Conference

02 مارس 2022 15:01:00 بحسب Nasdaq GlobeNewswire

Ultragenyx Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update

10 فبراير 2022 15:05:01 بحسب Nasdaq GlobeNewswire

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2021 Financial Results and Corporate Update

03 فبراير 2022 15:01:00 بحسب Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

02 فبراير 2022 15:05:00 بحسب Nasdaq GlobeNewswire

Ultragenyx Reports Preliminary 2021 Revenue and 2022 Revenue Guidance for Crysvita® in Ultragenyx Territories* And Dojolvi® Globally; Provides Pipeline Updates and 2022 Milestones

10 يناير 2022 07:00:02 بحسب Nasdaq GlobeNewswire

Ultragenyx to Present at H.C. Wainwright BioConnect Healthcare Conference

06 يناير 2022 15:01:00 بحسب Nasdaq GlobeNewswire